Seema Rogers has served as Head of Clinical Operations of Nurix since August 2019, first as Executive Director from August 219 to June 2021 and currently as Vice President since June 2021. Ms. Rogers has over 20 years of experience in clinical drug development, primarily in oncology. Before joining Nurix, Ms. Rogers served in a consulting capacity at IGM Biosciences, Stemcentrx (acquired by Abbvie) and Reflexion Medical. Prior to consulting, she worked at FivePrime Therapeutics where she built the company’s clinical operations organization, was responsible for defining operational strategy and managed the development of concurrent assets in oncology. Early in her career, Ms. Rogers served in positions of increasing responsibility at organizations including Cell Genesys, Geron, Genentech and Stanford University, where she managed global clinical trials in all phases of development. Ms. Rogers holds a B.S. from California Polytechnic State University, San Luis Obispo and an M.S. from The Johns Hopkins University.
Raf Lambrecht, Ph.D.
Raf Lambrecht has served as Head of Regulatory Affairs at Nurix since April 2020. Dr. Lambrecht is a Regulatory Affairs professional with over 25 years of experience in global regulatory strategy and execution. Prior to Nurix, he held regulatory positions with increasing responsibilities at Baxter, Bayer, and FibroGen. He has successfully filed and obtained approvals for INDs, CTAs, NDAs, and BLAs for high profile lead compounds in therapeutic areas of hemophilia, anemia, oncology, respiratory, autoimmune, and neuromuscular degenerative diseases. He brings to Nurix broad international regulatory expertise across the CMC, nonclinical and clinical regulatory areas, and broad experience solving complex regulatory issues in biologics and small molecules. In his early career, Dr. Lambrecht authored expert position papers and participated in pioneering Industry-Agency working groups for guideline development in Europe. He earned a master’s degree in Pharmacology and Ph.D. in Radiopharmaceuticals from the University of Gent, Belgium, and an MBA from St. Mary’s College in Moraga, California.
Marine Champsaur, Ph.D.
Marine Champsaur, Ph.D., has served as Vice President and Head of Medical Affairs since August 2022. Prior to joining Nurix, Dr. Champsaur provided scientific strategy and communications consulting services to early-stage biotech companies across a range of treatment modalities spanning the autoimmune and inflammatory disease, vaccine, and oncology space. Before that, Dr. Champsaur played a pivotal role in building the medical affairs function at Dermira, Inc., where she led the medical strategy and communications team. Early in her career, she held roles of increasing responsibility at UCB Pharma within immunology global medical affairs. Dr. Champsaur holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and a Ph.D. in Immunology from the University of California, San Francisco.
Kim Trahan
Kim Trahan has served as Vice President and Head of Program & Portfolio Management of Nurix since September 2021. Prior to joining Nurix, Ms. Trahan served in a variety of roles at Principia Biopharma, Inc., most recently as Vice President, Project & Portfolio Management, and participated in the company’s transition following its acquisition by Sanofi. She also served in program management roles at ProNai Therapeutics, Inc. (now Sierra Oncology), Adamas Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc., including participation in Onyx’s transition following its acquisition by Amgen. Early in her career she worked in corporate development at Poniard Pharmaceuticals, Inc. (formerly NeoRx) and as an analyst at Bay City Capital, LLC, a life sciences investment firm. Ms. Trahan holds a B.A. in Psychology and an M.B.A. in Management from Mills College in Oakland, CA.
Jen Dolan, M.S., M.B.A.
Jen Dolan has served as Vice President, Market Strategy, New Product Planning and Head of the BTK Franchise at Nurix since December 2021. Ms. Dolan leverages over 25 years of pharmaceutical and biotech experience to bring strategy and operational leadership to drug development. Her expertise includes corporate strategy, operations, product development, marketing, and business analytics. Prior to joining Nurix, Ms. Dolan led commercial teams at Principia Biopharma, Jazz Pharmaceuticals, Amgen, and McKesson. Between her years at McKesson and Amgen, she was founder and principal of Dolan & Associates, a biotech consulting company, where she established herself as an expert in commercial and channel strategy in the oncology sector. Ms. Dolan holds a Bachelor of Science in Engineering from University of California, Berkeley, a Master of Science in Engineering from Stanford University, and a Master of Business Administration in Strategy and Operations from the University of Minnesota.
Janine Powers, Ph.D.
Janine Powers, Ph.D., has served as Head of Translational Medicine at Nurix since September 2018. Dr. Powers has over 20 years of experience in drug development spanning multiple indications. Prior to joining Nurix, Dr. Powers worked in positions of increasing responsibility at FivePrime Therapeutics and was one of the founding members of the Clinical Biomarkers and Companion Diagnostics organization. During this time Dr. Powers managed biomarker strategy and execution on multiple global oncology trials evaluating both targeted therapeutics and cancer immunotherapies. Dr. Powers holds a B.S. in Biology from the University of California, San Diego, a Ph.D. in Integrative Biology and Physiology from the University of California, Los Angeles, and completed her postdoctoral fellowship at Stanford University School of Medicine.
James Nelson
James Nelson has served as Vice President of Quality Assurance at Nurix since September 2021. Mr. Nelson has 27 years of quality assurance experience in all aspects of biopharmaceutical development and commercialization. He previously served as Vice President of Quality Assurance at Neurocrine Biosciences, and before that as Head of Quality at Arena Pharmaceuticals. He has experience working for contract development manufacturing and research organizations and has successfully brought multiple drug candidates from development to commercialization. Mr. Nelson has worked at sites in the United States and internationally and has managed global teams to ensure consistent and effective quality programs built upon continuous improvement. He has extensive regulatory inspection experience having managed multiple pre-approval inspections, regulatory inspections, and audits. Mr. Nelson earned a Bachelor of Arts Degree in both Chemistry and Biology from Sonoma State University.
Frederick Cohen, Ph.D.
Fred Cohen joined Nurix in 2017 and has served as Head of Medicinal Chemistry since April 2020. He has more than 20 years of experience in small molecule drug discovery, spanning multiple therapeutic areas including oncology, neurodegeneration and antibiotics. Prior to joining Nurix, he served at Achaogen, Genentech, and Tularik. Dr. Cohen earned his bachelor’s degree in Chemistry from Occidental College and his Ph.D. in Chemistry from the University of California, Irvine.
John Kuriyan, Ph.D.
John Kuriyan, Ph.D., is an expert in the structural dynamics of ubiquitin ligases and other signaling complexes. Dr. Kuriyan is a Howard Hughes Medical Institute Investigator and a Professor of Molecular and Cell Biology and of Chemistry, University of California, Berkeley. Prior to that, he served as Assistant Professor and then Professor at Rockefeller University for 14 years. Dr. Kuriyan serves as a member of the Advisory Board at Carmot Therapeutics Inc. and is a Senior Editor at eLife, a new enterprise in high profile and open access scientific publishing. He is a member of the National Academy of Sciences, which awarded him the 2005 Richard Lounsbery Award. He holds a B.S. in chemistry from Juniata College, Pennsylvania, and a Ph.D. from the Massachusetts Institute of Technology.
Michael Rapé, Ph.D.
Michael Rapé, Ph.D., is a leader in the biology of ubiquitin-dependent cell cycle progression and carcinogenesis. He is a Howard Hughes Investigator and a Professor of Cell and Developmental Biology at the University of California, Berkeley. He started his own lab at the University of California, Berkeley in the fall of 2006, where he has developed novel screening tools to identify the ubiquitylation enzymes that are important for cell division and differentiation and pair them with the proteins they target. Prior to that, he completed his postdoctoral research at Harvard Medical School in the lab of Marc Kirschner. In recognition of his creativity and productivity, Dr. Rapé was named a Pew Scholar and received the NIH Director’s New Innovator Award in 2007. He has also won prestigious fellowships from the Human Frontier Science Program and the European Molecular Biology Organization. Dr. Rapé studied Biochemistry at the University of Bayreuth in Germany and received his Ph.D. at the MPI in Martinsried, Germany in the lab of Stefan Jentsch.
'